Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quicksilver II Non-inferiority Randomized Controlled Trial: Direct-to-surgery or Neoadjuvant Chemotherapy and Surgery in Margin-clear Stage II or III Rectal Cancer

NCT07688135 is registered in ClinicalTrials.gov with Mount Sinai Hospital, Canada as lead sponsor.

NCT NCT07688135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07688135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quicksilver II Non-inferiority Randomized Controlled Trial: Direct-to-surgery or Neoadjuvant Chemotherapy and Surgery in Margin-clear Stage II or III Rectal Cancer
Lead sponsor
Mount Sinai Hospital, Canada
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2028
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii rectal cancer, stage iii rectal cancer